Effects of dipeptidyl peptidase
iv inhibition on arterial blood pressure.
Vandekerckhove et al., "Left ventricular diastolic dysfunction and myocardial stiffness in diabetic mice is attenuated by inhibition of dipeptidyl peptidase
4," Cardiovascular Research, vol.
The identification of peptidases
of the gastric fluid of the American lobster was carried out by comparing the electrophoresis composition of control sample with the peptidase
class-specific inhibitor-treated samples (Fig.
Doty et al., "Dipeptidyl peptidase
IV inhibitor treatment stimulates [beta]-cell survival and islet neogenesis in streptozotocin-induced diabetic rats," Diabetes, vol.
niger acid proteinase A or aspergillopepsin II) was insensitive to pepsin-type proteinase inhibitors, such as DAN, EPNP and pepstatin A, it continued to attract our attention and was long been thought to be a kind of non-pepsin type (or pepstatin-insensitive) aspartic peptidase
. (166-169) Recently it was shown not to be an aspartic peptidase
but a glutamic peptidase
which has a catalytic Glu residue at the active site and thus renamed aspergilloglutamic peptidase
activities were similar among treatments.
Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase
IV inhibitor for the treatment of Type 2 diabetes.
Tokyo, Japan, June 15, 2006 - (JCN) - Ono Pharmaceutical and Banyu Pharmaceutical have obtained positive results in the recent clinical trials of sitagliptin, a dipeptidyl peptidase
IV (DPP4) inhibitor.
(OSI) Prosidion's lead compound, PSN9301, is a Dipeptidyl Peptidase
IV (DPIV) inhibitor currently in Phase II clinical trials.
A protein having "multifunctional activity," is defined herein as including at least one of a chymotrypsin, trypsin, collagenase, elastase or exo peptidase
activity or asialo GM.sub.1 ceramide binding activity.
Despite this change, HAP is an active protease with distinct properties, and together with a series of cysteine and metallo-proteases and a dipeptidyl peptidase
, provides attractive focus for antimalarial drug development.
Oncopeptides AB (STO:ONCO), a pharmaceutical company developing drugs for the treatment of cancer, announced on Wednesday that data from its phase 1/2 O-12-M1 study evaluating melflufen, a lipophilic peptide-conjugated alkylator belonging to the novel class of peptidase
enhanced cytotoxics, in the treatment of relapsed/refractory multiple myeloma (RRMM), have been selected for poster presentation at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting taking place between 31 May 2019 to 4 June 2019 in Chicago.